Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir

• Published in: Revista do Instituto de Medicina Tropical de São Paulo Vol. 60; pp. e29 - 8
• Main Authors: Gomes, Lenyta Oliveira, Teixeira, Marina Rodrigues, Rosa, Júnior André da, Feltrin, Alberi Adolfo, Rodrigues, João Paulo V, Vecchi, Mariane D'Avila, Carneiro, Jane Meire M, Noblat, Lúcia de Araújo C B, Chachá, Silvana Gama F, Martinelli, Ana de Lourdes C, Pereira, Leonardo Regis L, Silveira, Marysabel Pinto T, Blatt, Carine Raquel, Farias, Mareni Rocha
• Format: Journal Article
• Language: English
• Published: Brazil Instituto de Medicina Tropical de Sao Paulo 01.01.2018; Instituto de Medicina Tropical; Universidade de São Paulo (USP)
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - economics; Chronic hepatitis C treatment; Clinical Protocols; Decision Making; Drug Therapy, Combination; Female; Genotype; Hepacivirus - genetics; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - economics; High cost medicines; Humans; Interferon-alpha - administration & dosage; Male; Middle Aged; Oligopeptides - administration & dosage; Oligopeptides - economics; Original; Polyethylene Glycols - administration & dosage; Proline - administration & dosage; Proline - analogs & derivatives; Proline - economics; Protease inhibitors; Protease Inhibitors - administration & dosage; Protease Inhibitors - economics; Real life studies; Recombinant Proteins - administration & dosage; Retrospective Studies; Ribavirin - administration & dosage; TROPICAL MEDICINE; High cost medicines; Chronic hepatitis C treatment; Protease inhibitors; Real life studies

In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were dis...